21 – 30 of 74
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2011
-
Mark
The three ZNT8 autoantibody variants together improve the diagnostic sensitivity of childhood and adolescent type 1 diabetes.
(
- Contribution to journal › Article
- 2008
-
Mark
The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments
(
- Contribution to journal › Article
-
Mark
The burden of rheumatoid arthritis and access to treatment: uptake of new therapies
(
- Contribution to journal › Article
-
Mark
Children developing type 1 diabetes before 6 years of age have increased linear growth independent of HLA genotypes.
(
- Contribution to journal › Article
-
Mark
The burden of rheumatoid arthritis and access to treatment: determinants of access
(
- Contribution to journal › Article
-
Mark
THE COST-EFFECTIVENESS OF GROWTH HORMONE REPLACEMENT THERAPY WITH GENOTROPIN (R) IN HYPOPITUITARY ADULT PATIENTS
(
- Contribution to journal › Published meeting abstract
-
Mark
Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden.
(
- Contribution to journal › Article
-
Mark
Symbicort SMART - Effective treatment at a lower cost
(
- Contribution to journal › Published meeting abstract
-
Mark
Temporal trends of HLA genotype frequencies of type 1 diabetes patients in Sweden from 1986 to 2005 suggest altered risk.
(
- Contribution to journal › Article
- 2007
-
Mark
Latitude, socioeconomic prosperity, mobile phones and hip fracture risk.
(
- Contribution to journal › Article